ALBANY, N.Y., Oct 28, 2010 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today announced that Kevin J. Gould, 56, was elected to its Board of Directors at the Company's annual shareholders meeting on October 18, 2010. Mr. Gould is the former Chief Operating Officer of Tyco Healthcare, and his election fills the vacancy created by the retirement of Paul S. Echenberg from the Company's Board.

"We welcome Kevin to our Board of Directors. We believe his broad leadership and executive experience in the medical device industry, as well as his extensive knowledge of operational, financial, business and strategic issues, will be instrumental as we continue to pursue our growth and profitability objectives," said Vincent Bucci, Chairman of the Board for AngioDynamics.

In addition, the Company's Board of Directors appointed Paul Echenberg as Director Emeritus.

"Paul has been a significant contributor to AngioDynamics for the past 20 years, and we are very pleased that he will continue to provide his expertise as a trusted advisor to the Board in this role," Mr. Bucci said. "On behalf of the Board and the executive team, I extend our great appreciation to Paul for his long service to AngioDynamics, including his chairmanship of the Board from 2004 to 2007."

Mr. Gould has more than 30 years of healthcare industry experience. From 1991 until 2009, he held various management positions at Tyco Healthcare, now known as Covidien after going public in 2007. Prior to serving as the company's COO, he was President of North America operations of Tyco Healthcare. Mr. Gould has served on the Board of Trustees of St. Elizabeth's Hospital in Brighton, Massachusetts. He earned his M.B.A. from Anna Maria College in Paxton, Mass., and his B.A. from St. Anselm's College in Manchester, N. H.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. AngioDynamics' diverse product lines include market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.

SOURCE: AngioDynamics, Inc.

AngioDynamics, Inc.
Company Contact:
D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
jgersuk@AngioDynamics.com
or
EVC Group, Inc.
Investor Relations Contacts:
Doug Sherk/ Greg Gin, 415-896-6820
dsherk@evcgroup.com; ggin@evcgroup.com
Media Contact:
Chris Gale, 646-201-5431
cgale@evcgroup.com

Copyright Business Wire 2010